THE RISING VACCINE SUPERPOWER
Can India sustain the pandemic driven momentum ?
India ’ s vaccines sector has got a push due to COVID-19 and now it proudly dominates the biopharma market . Here we analyze the dynamism and outlook of the sector .
BY BIOVOICE EDITORIAL TEAM
Just a few decades ago it was quite unimaginable that India could ever produce a vaccine that would be both affordable and globally acceptable at the same time . An indigenous vaccine developed through platforms fully innovated in India was more like a pipe-dream to naysayers .
Proving them wrong , not only did Hyderabad based Bharat Biotech achieve a remarkable feat of US $ 1 Rotavirus vaccine in 2016 , it went on to develop Covaxin , a fully indigenous vaccine against Covid-19 during the the peak of the pandemic in 2021 . One of
India ' s earliest private vaccine manufacturers , Serum Institute of India that steadily expanded its capabilities , started offering a wide range of vaccines post 2001 . Be it Shantha Biotech , Biological E , Gennova Biopharma , or Panacea Biotech , all of these names have done their bit in strengthening the sector .
The journey that began from Kasauli in 1904 with the first vaccine research institute to establishment of BCG vaccine factory in 1948 , and first indigenous vaccine against polio in 1980 , kept getting
12
BioVoiceNews | October 2022